Annette Bianchi, MBA
Annette has over 35 years of venture capital investment experience with over 32 years as a General Partner or Managing Director.
Annette was a seed investor and played a key role in the formation of Cephalon (CEPH) which was acquired by Teva Pharmaceuticals for $6.8 billion. She was also a seed investor in CellPro (CPRO), ProDuct (acquired by Cytyc), Vivant (acquired by Tyco), and InnerDyne (merged with CardioPulmonics – acquired by Covidien).
She has invested in numerous other companies including Anthera (ANTH), Conceptus (CPTS-acquired by Bayer for $1.1 billion), Coulter (acquired by Corixa for $900M), Ligand (LGND), Oacis (OCIS – acquired by SAIC), Orquest (acquired by DePuy), Phase Forward (PFWD – acquired by Oracle), Targegen/Impact (acquired by Sanofi-Aventis for $560M/spun out as Impact BioMedicines and then acquired by Celgene for $7 billion), and Telik (TELK).
Annette began her venture capital career in 1985 as an Associate and later a General Partner at Burr, Egan, Deleage & Company. In 1992, she joined Weiss, Peck & Greer Venture Partners as a General Partner and subsequently became a Managing Director at Pacific Venture Group in 1999. In 2004, she became a Managing Director at VantagePoint Capital Partners until she founded Red Tailed Hawk Venture Partners.
Annette is a graduate of the University of Pennsylvania (BSE and MSE) in Biomedical Engineering and The Wharton School (MBA).
More Team Members
Bob Abraham, PhD
Mike Diem, MD, MBA
Brian McVeigh, MBA
Bruce Pitt, MD, PhD
Tarek Samad, PhD
Harinder Singh, PhD